Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis

Basit Öğe Kaydı
dc.authoridPınar Yurdakul Mesutoğlu / 0000-0002-0043-7187en_US
dc.authorscopusidPınar Yurdakul Mesutoğlu / 57213609711
dc.authorwosidPınar Yurdakul Mesutoğlu / FNY-1633-2022en_US
dc.contributor.authorÇubukçu, Hikmet Can
dc.contributor.authorYurdakul Mesutoğlu, Pınar
dc.contributor.authorSeval, Güldane Cengiz
dc.contributor.authorBeksac, Meral
dc.date.accessioned2022-12-08T07:59:03Z
dc.date.available2022-12-08T07:59:03Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractThe present systematic review aimed to investigate natural killer (NK) cell ex vivo expansion protocols within the scope of clinical trials targeting hematological cancer and to conduct a meta-analysis to assess the effect of NK cell infusion on survival. Research articles of clinical studies in which cell products produced by ex vivo expansion, consisting of a certain amount of NK cells and infused to patients with hematological cancer, were included in the systematic review. We conducted a proportion analysis with random effects for product purity and viability values. Studies having control groups were included in the survival meta-analysis. Among 11.028 identified records, 21 were included in the systematic review. We observed statistically significant heterogeneity for viability (I2 = 97.83%, p < 0.001) and purity values (I2 = 99.95%, p < 0.001), which was attributed to the diversity among isolation and expansion protocols. In addition, the survival meta-analysis findings suggested that NK cell therapy favors disease-free survival (DFS) of patients with myeloid malignancies but limited to only two clinical studies (odds ratio = 3.40 (confidence interval:1.27-9.10), p = 0.01). While included protocols yielded cell products with acceptable viability, the utility of immunomagnetic methods; feeder cells such as K562 expressing membrane-bound IL15 and 4-1BBL or expressing membrane-bound IL21 and 4-1BBL might be preferable to achieve better purity. In conclusion, NK cell therapy has a potential to improve DFS of patients with myeloid malignancies.en_US
dc.identifier.citationÇubukçu, H. C., Mesutoğlu, P. Y., Seval, G. C., & Beksaç, M. (2022). Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis. Clinical and Experimental Medicine, 1-31.en_US
dc.identifier.doi10.1007/s10238-022-00923-zen_US
dc.identifier.issn1591-8890en_US
dc.identifier.issn1591-9528en_US
dc.identifier.scopus2-s2.0-85141365824en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://dx.doi.org/10.1007/s10238-022-00923-z
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3421
dc.identifier.wosWOS:000878916100001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorYurdakul Mesutoğlu, Pınar
dc.language.isoenen_US
dc.publisherSPRINGER-VERLAG ITALIA SRLen_US
dc.relation.ispartofCLINICAL AND EXPERIMENTAL MEDICINEen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNatural Killeren_US
dc.subjectExpansionen_US
dc.subjectImmunotherapyen_US
dc.subjectHematological Malignanciesen_US
dc.subjectCanceren_US
dc.titleEx vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysisen_US
dc.typeOtheren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
s10238-022-00923-z.pdf
Boyut:
3.94 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu